Skip to main content

Table 2 Change in health status and symptom scores of 4 the groups of COPD patients at exacerbations compared to stable visits

From: COPD exacerbation severity and frequency is associated with impaired macrophage efferocytosis of eosinophils

  A (n = 10) B (n = 16) C (n = 19) D (n = 58) p value
Δ CRQ Fatigue (unit) -1.36 (-2.61 to -0.12)* -1.33 (-2.35 to -0.31)* -1.11 (-1.76 to -0.45)* -1.00 (-2.61 to -0.12)* 0.78
Δ CRQ Dyspnoea (unit) -1.49 (-2.92 to -0.05)* -1.05 (-2.32 to 0.21)* -1.04 (-1.41 to -0.67)* -0.57 (-0.98 to -0.15)* 0.34
Δ CRQ Emotion (unit) -1.22 (-1.52 to -0.91)* -1.07 (-2.00 to -0.14)* -0.62 -1.27 to 0.02)* -0.89 (-1.31 to -0.46)* 0.67
Δ CRQ Mastery (unit) -0.99 (-2.33 to 0.36)* -0.97 (-2.28 to 0.34)* -1.10 (-1.99 to -0.21)* -0.75 (-1.09 to -0.41)* 0.59
Δ CRQ total (unit) -1.26 (-2.21 to -0.32)* -1.12 (-1.99 to -0.22)* -0.97 (-1.49 to -0.44)* -0.79 (-1.04 to -0.55)* 0.54
Δ VAS cough (mm) 22 (3 to 42)* 35 (21 to 48)* 7 (3 to 42)* 27 (18 to 36)* 0.06
Δ VAS dyspnoea (mm) 34 (3 to 65)* 35 (20 to 51)* 17 (-2 to 35) 25 (17 to 33)* 0.31
Δ VAS sputum production (mm) 8 (-32 to 49) 24 (-2 to 50) 9 (-2 to 21) 21 (12 to 29)* 0.45
Δ VAS sputum purulence (mm) 28 (-13 to 68) 18 (-5 to 42) 31(17 to 45)* 15 (5 to 24)* 0.36
  1. Data presented as mean (95% CI) unless stated; *p < 0.05 stable versus exacerbation.